1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The intratumoral microbiota biomarkers for predicting survival and efficacy of immunotherapy in patients with ovarian serous cystadenocarcinoma

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Ovarian serous cystadenocarcinoma, accounting for about 90% of ovarian cancers, is frequently diagnosed at advanced stages, leading to suboptimal treatment outcomes. Given the malignant nature of the disease, effective biomarkers for accurate prediction and personalized treatment remain an urgent clinical need.

          Methods

          In this study, we analyzed the microbial contents of 453 ovarian serous cystadenocarcinoma and 68 adjacent non-cancerous samples. A univariate Cox regression model was used to identify microorganisms significantly associated with survival and a prognostic risk score model constructed using LASSO Cox regression analysis. Patients were subsequently categorized into high-risk and low-risk groups based on their risk scores.

          Results

          Survival analysis revealed that patients in the low-risk group had a higher overall survival rate. A nomogram was constructed for easy visualization of the prognostic model. Analysis of immune cell infiltration and immune checkpoint gene expression in both groups showed that both parameters were positively correlated with the risk level, indicating an increased immune response in higher risk groups.

          Conclusion

          Our findings suggest that microbial profiles in ovarian serous cystadenocarcinoma may serve as viable clinical prognostic indicators. This study provides novel insights into the potential impact of intratumoral microbial communities on disease prognosis and opens avenues for future therapeutic interventions targeting these microorganisms.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s13048-024-01464-7.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Role of the microbiota in immunity and inflammation.

            The microbiota plays a fundamental role on the induction, training, and function of the host immune system. In return, the immune system has largely evolved as a means to maintain the symbiotic relationship of the host with these highly diverse and evolving microbes. When operating optimally, this immune system-microbiota alliance allows the induction of protective responses to pathogens and the maintenance of regulatory pathways involved in the maintenance of tolerance to innocuous antigens. However, in high-income countries, overuse of antibiotics, changes in diet, and elimination of constitutive partners, such as nematodes, may have selected for a microbiota that lack the resilience and diversity required to establish balanced immune responses. This phenomenon is proposed to account for some of the dramatic rise in autoimmune and inflammatory disorders in parts of the world where our symbiotic relationship with the microbiota has been the most affected. Copyright © 2014 Elsevier Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Nomograms in oncology: more than meets the eye.

              Nomograms are widely used as prognostic devices in oncology and medicine. With the ability to generate an individual probability of a clinical event by integrating diverse prognostic and determinant variables, nomograms meet our desire for biologically and clinically integrated models and fulfill our drive towards personalised medicine. Rapid computation through user-friendly digital interfaces, together with increased accuracy, and more easily understood prognoses compared with conventional staging, allow for seamless incorporation of nomogram-derived prognosis to aid clinical decision making. This has led to the appearance of many nomograms on the internet and in medical journals, and an increase in nomogram use by patients and physicians alike. However, the statistical foundations of nomogram construction, their precise interpretation, and evidence supporting their use are generally misunderstood. This issue is leading to an under-appreciation of the inherent uncertainties regarding nomogram use. We provide a systematic, practical approach to evaluating and comprehending nomogram-derived prognoses, with particular emphasis on clarifying common misconceptions and highlighting limitations.
                Bookmark

                Author and article information

                Contributors
                haoqin@bjmu.edu.cn
                yanyifangyanyf@hotmail.com
                Journal
                J Ovarian Res
                J Ovarian Res
                Journal of Ovarian Research
                BioMed Central (London )
                1757-2215
                5 July 2024
                5 July 2024
                2024
                : 17
                : 140
                Affiliations
                [1 ]GRID grid.506261.6, ISNI 0000 0001 0706 7839, State Key Laboratory of Molecular Oncology, , National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, ; No.17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021 China
                [2 ]Department of Medical Records, Air Force Medical Center, PLA, Air Force Medical University, ( https://ror.org/00ms48f15) Beijing, China
                [3 ]State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, ( https://ror.org/04wwqze12) No.49 North Huayuan Road, Haidian District, Beijing, 100191 China
                [4 ]National Clinical Research Center for Obstetrics and Gynecology, (Peking University Third Hospital), ( https://ror.org/04wwqze12) Beijing, China
                [5 ]Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education, ( https://ror.org/02v51f717) Beijing, China
                [6 ]GRID grid.411642.4, ISNI 0000 0004 0605 3760, Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, ; Beijing, China
                [7 ]GRID grid.24696.3f, ISNI 0000 0004 0369 153X, Medical Center for Human Reproduction, Beijing Chao-Yang Hospital, , Capital Medical University, ; Beijing, China
                [8 ]Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, ( https://ror.org/04jztag35) Beijing, China
                Article
                1464
                10.1186/s13048-024-01464-7
                11227176
                38970121
                a8918b69-3ba9-4a62-87c4-ee6928a13da7
                © The Author(s) 2024

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 5 February 2024
                : 26 June 2024
                Funding
                Funded by: Beijing Natural Science Foundation
                Award ID: L232075
                Funded by: the National Natural Science Foundation of China
                Award ID: 82304151
                Award ID: 32100647
                Funded by: the Fundamental Research Funds for the Central Universities
                Award ID: 3332023033
                Funded by: National Clinical Research Center for Obstetrics and Gynecology (Peking University Third Hospital)
                Award ID: No. BYSYSZKF2023014
                Funded by: the Cancer Hospital of Chinese Academy of Medical Sciences-Shenzhen Hospital Cooperation Fund
                Award ID: CFA202202023
                Funded by: Key Clinical Project of Peking University Third Hospital
                Award ID: No. BYSYZD2023036
                Categories
                Research
                Custom metadata
                © BioMed Central Ltd., part of Springer Nature 2024

                Obstetrics & Gynecology
                intratumoral microbiota,ovarian serous cystadenocarcinoma,tcga-ov,microbial biomarker,nomogram

                Comments

                Comment on this article